


**Supplemental TABLE 1: Characteristics Associated with Blanching Defects at Each Evaluated Pressure Point**


Blanching defect site	Skull			Scapulae			Sacrum			Calcaneus		
	Absent	Present	P	Absent	Present	P	Absent	Present	P	Absent	Present	P
<b>Age (yrs)</b>	56.2±14.7 (26-89)	64.8±14.5 (29-83)	0.019*	53.2±14.3 (26-83)	66.1±13 (26-89)	<0.0001*	56.8±15.3 (26-89)	65.1±13 (37-83)	0.037*	62.3±15.9 (30-83)	55.3±15.8 (26-89)	0.233
<b>Weight (kg)</b>	85.8±16.1 (53-131.7)	87.7±19.5 (53.1-148)	0.650	86.2±19.5 (53-148)	86.7±13.7 (59-119)	0.907	87.9±18.6 (53-148)	81.8±10.5 (68.4-102.5)	0.079	79.7±11.8 (57.8-101.2)	83.4±15.5 (53-113)	0.505
<b>Height (cm)</b>	173±10 (152-196)	176±10 (160-196)	0.200	171±10 (152-193)	178±8 (165-196)	0.002*	173±9 (152.4-193)	178±9 (163-196)	0.047*	173±6 (165-180)	171±9 (152-196)	0.514
<b>BMI (kg/m<sup>2</sup>)</b>	28.6±4.9 (19.4-40.4)	28.2±5.9 (19.4-46.8)	0.769	29.3±5.8 (19.4-46.8)	27.4±4.3 (19.4-36.6)	0.118	29.3±5.5 (19.4-46.8)	25.9±3.1 (19.4-31.1)	0.001*	26.7±3.5 (20-32)	28.7±5.2 (19.4-40.4)	0.277
<b>Injected dose (MBq)</b>	244±143 (17-394)	283±92 (18-370)	0.159	235±145 (17-394)	283±104 (19-392)	0.092	239±137 (17-394)	308±90 (21-390)	0.016*	251±144 (17-379)	239±143 (18-394)	0.829
<b>Fasting duration (Hrs)</b>	9.6±3.6 (4-20)	8.0±3.7 (4-16)	0.078	9.9±3.1 (4-18)	8.1±4.2 (4-20)	0.045*	9.1±3.8 (4-20)	9.1±3.4 (4-15)	0.999	9.3±3 (4-12)	9.7±3.7 (4-20)	0.805
<b>Blood glucose (mg/dL)</b>	94.1±20.5 (39-154)	99.5±5.8 (92-105)	0.531	94.1±19.9 (39-154)	97.6±17.6 (65-128)	0.614	94.3±20.6 (39-154)	96.8±14.3 (79-128)	0.720	105.3±30.9 (79-154)	92.4±16.9 (39-130)	0.325
<b>Sex</b>												
<i>Female</i>	15	3	0.156	17	1	<0.0001*	17	1	0.033*	2	16	0.688
<i>Male</i>	38	21		26	33		41	18		7	31	
<b>BMI categories</b>												
<i>Normal</i>	11	7	0.736	9	9	0.447	11	7	0.043*	3	11	0.342
<i>Overweight</i>	25	10		18	17		25	10		5	19	
<i>Obese</i>	17	7		16	8		22	2		1	17	
<b>Disease</b>												
<i>Cancer</i>	19	18	0.006*	11	26	<0.0001*	26	11	0.662	5	14	0.362
<i>CVD</i>	8	2		9	1		8	2		1	7	
<i>Healthy</i>	26	4		23	7		24	6		3	26	
<b>Used tracer</b>												

Blanching defect site	Skull			Scapulae			Sacrum			Calcaneus		
	Absent	Present	<i>P</i>	Absent	Present	<i>P</i>	Absent	Present	<i>P</i>	Absent	Present	<i>P</i>
<i>FDG</i>	41	6	<0.0001*	37	10	<0.0001*	37	10	0.425	6	35	0.688
<i>Fluciclovine</i>	12	18		6	24		21	9		3	12	
<b>Injected activity</b>												
<i>Low dose</i>	13	2	0.160	11	4	0.009*	14	1	0.185	2	12	1.000
<i>Intermediate dose</i>	8	2		9	1		8	2		1	7	
<i>Standard dose</i>	32	20		23	29		36	16		6	28	
<b>Arms position</b>												
<i>Above</i>	11	18	<0.0001*	5	24	<0.0001*	20	9	0.414	3	12	0.688
<i>Side</i>	42	6		38	10		38	10		6	35	
<b>AC CT Dose</b>												
<i>Ultra-Low-dose</i>	34	6	0.003*	32	8	<0.0001*	32	8	0.429	4	33	0.247
<i>Low-dose</i>	19	18		11	26		26	11		5	14	
<b>Fused PET/CT misregistration</b>												
<i>No</i>	39	21	0.240	33	27	1.000	45	15	1.000	5	35	0.259
<i>Yes</i>	14	3		10	7		13	4		65	12	
<b>Knee cushion</b>												
<i>No</i>	3	0	0.548	2	1	1.000	2	1	1.000	1	2	0.415
<i>Yes</i>	50	24		41	33		56	18		8	45	
<b>Back cushion</b>												
<i>No</i>	49	24	0.304	40	33	0.626	54	19	0.567	8	45	0.259
<i>Yes</i>	4	0		3	1		4	0		1	2	


\* Statistically significant




Supplemental Figure 1.



Supplemental Figure 2.



Supplemental Figure 3.



Supplemental Figure 4.